Literature DB >> 1313847

Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16.

L Chen1, M T Mizuno, M C Singhal, S L Hu, D A Galloway, I Hellström, K E Hellström.   

Abstract

Human papillomavirus (HPV) type 16 has been implicated in the etiology of cervical carcinomas, but it is unknown whether HPV-specific immunity can function in controlling the growth of HPV-associated carcinomas. We previously demonstrated that CD8+ T lymphocytes can inhibit the in vivo outgrowth of murine tumor cells transfected with the HPV-16 E7 gene and have now established a murine model to study the CTL responses to the E6 oncoprotein of HPV-16. Immunization of C3H/HeN mice with syngeneic fibroblasts expressing a transfected HPV-16 E6 gene induced regression of transplanted tumors expressing this gene. Populations of CTL isolated from the spleens of mice whose E6+ tumors had regressed were shown to specifically lyse E6+ target cells. The cytolytic activity was mediated by CD8+ CTL in a MHC restricted pattern. These data and our previous findings with transfected tumor cells expressing the E7 gene, support the conclusion that tumor cells associated with HPV-16 can be inhibited by CTL specific for molecules encoded by the HPV-16 E6 and E7 genes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313847

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 2.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

3.  Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.

Authors:  M W Carroll; W W Overwijk; D R Surman; K Tsung; B Moss; N P Restifo
Journal:  J Natl Cancer Inst       Date:  1998-12-16       Impact factor: 13.506

Review 4.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

5.  Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.

Authors:  D W Liu; Y P Tsao; J T Kung; Y A Ding; H K Sytwu; X Xiao; S L Chen
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  A simple method for the propagation of cervical lymphocytes.

Authors:  A B Moscicki; S D Hunter; S Garland; M Quinn; S M Crowe; K Shortman; D Stites
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

7.  Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.

Authors:  Qinghua Feng; Huafeng Wei; Janice Morihara; Joshua Stern; Mujun Yu; Nancy Kiviat; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Gynecol Oncol       Date:  2012-07-22       Impact factor: 5.482

8.  Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits.

Authors:  Antonia Radaelli; Eleana Pozzi; Sole Pacchioni; Carlo Zanotto; Carlo De Giuli Morghen
Journal:  J Transl Med       Date:  2010-04-21       Impact factor: 5.531

9.  Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.

Authors:  Yi-Fang Chen; Chih-Wei Lin; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Dissecting the dynamics of dysregulation of cellular processes in mouse mammary gland tumor.

Authors:  Wieslawa I Mentzen; Matteo Floris; Alberto de la Fuente
Journal:  BMC Genomics       Date:  2009-12-13       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.